Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Folic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.70 |
| ▸ | TYMS | P04818 | 3/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | POLB | P06746 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | DHFR | P00374 | 6/20 | 0.64 |
| ▸ | GART | P22102 | 3/20 | 0.64 |
| ▸ | ATIC | P31939 | 2/20 | 0.64 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folic Acid SCHEMBL28152308 | 0.98 | TYMS (0.91) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29357550 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29441959 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29388311 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL403054 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL248712 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL16492117 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL3877 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL332170 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL29624885 | 0.97 | TYMS (1.00) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106310261-B | Preparation method with magnetic and folic acid dual-target composite nano materials | 新乡医学院 | 2019-10-01 | — | — | CN | claimed |
| CN-105778139-B | The construction method of functional form imitating cell outer-layer film stereochemical structure coating | 西北大学 | 2019-01-25 | — | — | CN | claimed |
| CN-106310261-A | Preparation method of composite nano material with magnetism and folic acid double targeting | 新乡医学院 | 2017-01-11 | — | — | CN | claimed |
| CN-105778139-A | Method for constructing functional imitated cellulosa membrane stereo structure coating | 西北大学 | 2016-07-20 | — | — | CN | claimed |
| CN-106924756-B | Polymer nanosphere with cancer cell targeting recognition function and preparation method thereof | 清华大学 | 2020-12-29 | — | — | CN | disclosed |
| CN-106310261-B | Preparation method with magnetic and folic acid dual-target composite nano materials | 新乡医学院 | 2019-10-01 | — | — | CN | disclosed |
| CN-106310261-B | Preparation method with magnetic and folic acid dual-target composite nano materials | 新乡医学院 | 2019-10-01 | — | — | CN | disclosed |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-04-11 | — | — | US | disclosed |
| CN-105778139-B | The construction method of functional form imitating cell outer-layer film stereochemical structure coating | 西北大学 | 2019-01-25 | — | — | CN | disclosed |
| CN-107674220-A | A kind of photocrosslinking nano epoxy resin and preparation method thereof | 成都昂多生物技术有限责任公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-106924756-A | A kind of polymer nanocomposite ball with cancer cell targets identification function and preparation method thereof | 清华大学 | 2017-07-07 | — | — | CN | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| CN-101352572-A | Method for preparing folacin-carboxyl complexes | UNIV FUDAN (CN) | 2009-01-28 | — | — | CN | disclosed |
| CN-101239190-A | Vitamin receptor binding drug delivery conjugates | ENDOCYTE INC (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-100381177-C | Vitamin receptor binding drug delivery conjugates | ENDOCYTE INC (US) | 2008-04-16 | — | — | CN | disclosed |
| CN-1761488-A | Vitamin receptor binding drug delivery conjugates | ENDOCYTE INC (US) | 2006-04-19 | — | — | CN | disclosed |
| EP-1592457-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | Endocyte, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069159-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | VDR, CYP2R1, CYP24A1 | ADORA3 690/4885TYMS 785/4885KDM4E 3274/4885 |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | ADORA3 280/4885TYMS 1343/4885KDM4E 2503/4885 |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | ADORA3 280/4885TYMS 1343/4885KDM4E 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.